Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2018 March;60(1) > Panminerva Medica 2018 March;60(1):29-34

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

 

REVIEW   Freefree

Panminerva Medica 2018 March;60(1):29-34

DOI: 10.23736/S0031-0808.18.03405-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Fecal calprotectin: beyond intestinal organic diseases

Gian P. CAVIGLIA 1 , Davide G. RIBALDONE 1, Chiara ROSSO 1, Giorgio M. SARACCO 1, 2, Marco ASTEGIANO 2, Rinaldo PELLICANO 2

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Unit of Gastroenterology and Hepatology, Città della Salute e della Scienza, Molinette Hospital, Turin, Italy


PDF


Fecal calprotectin (FC) is a calcium-binding protein with antimicrobic, imunomodulatory and antiproliferative properties that is mainly found in the cytoplasm of neutrophil granulocytes. During the last decades, FC became an increasingly useful tool both for gastroenterologists and for general practitioners for distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome. FC correlates with clinical scoring systems and endoscopic lesions in IBD and is considered a reliable biomarker for the prediction of clinical relapse or remission. However, FC elevation could be observed also in other gastrointestinal pathological conditions including infective colitis, microscopic colitis, eosinophilic colitis, adenomas and colorectal cancer. In addition, there are several non-pathological conditions that can lead to altered FC values. In this review, we aimed to point out individual, environmental and method-related factors that can affect FC measurement and thus its clinical interpretation.


KEY WORDS: Biomarkers - Inflammatory bowel diseases - S100 Proteins

inizio pagina